Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Diagnostic Methods Compared for Human Granulocytic Anaplasmosis

By LabMedica International staff writers
Posted on 02 May 2019
Human granulocytic anaplasmosis (HGA) is a tick-borne intracellular bacterial infection caused by Anaplasma phagocytophilum. More...
The disease is present in North America, Europe, and northern Asia, areas with Ixodes ricinus ticks, the primary vector for transmission to humans.

Diagnosis requires the isolation of A. phagocytophilum in blood culture, the presence of morulae in polymorphonuclear cells after May Grünwald-Giemsa staining of peripheral blood smears, positive serologic results (seroconversion or high titer of specific antibodies), or a positive A. phagocytophilum polymerase chain reaction (PCR) result.

A large team of scientists collaborating with the University of Strasbourg (Strasbourg, France) conducted a prospective, multicenter study, and enrolled symptomatic patients living in Alsace, a region of northeastern France where tick-borne diseases are highly endemic. The investigators performed DNA extraction, PCR, and serologic testing blinded to sample identification. The PCR targeted the A. phagocytophilum msp2/p44 gene. They performed serologic testing using the Anaplasma phagocytophilum IFA IgG assay. Trained staff examined May Grünwald-Giemsa–stained smear preparations of whole blood samples for intracellular morulae.

Of the 130 patients, 19 had confirmed anaplasmosis diagnoses and 36 were controls with confirmed non-anaplasmosis diagnoses (infections with Borrelia burgdorferi, Epstein-Barr virus, cytomegalovirus, HIV, tick-borne encephalitis virus, Leptospira spp., Babesia spp., parvovirus B19, hantavirus, Francisella tularensis, Plasmodium spp., and Aeromonas spp.). Of the patients with HGA, 16/19 (84.2%) met the serologic criteria and 14/19 (73.7%) met the PCR criteria. Fever, the most frequent symptom (89%), was associated with joint and muscle pain. Cytopenia of platelets, neutrophils, or both (74%) and elevated liver enzyme levels (63%) were frequently present.

Calculations of the diagnostic value of each test method showed that PCR had a sensitivity of 0.74 and a specificity of 1 and blood smear staining had a sensitivity of 0.21 and a specificity of 1. Seroconversion or a 4-fold increase of antibody titer had a sensitivity of 0.32 and specificity of 0.97, an antibody titer >1:256 had a sensitivity of 0.58 and specificity of 0.97, and overall serology had a sensitivity of 0.84 and specificity of 0.97.

The authors concluded that the presentation of fever in a patient with a history of tick bite does not qualify for an anaplasmosis diagnosis; microbiological tests need to be performed. For anaplasmosis, PCR testing appears to be the most effective diagnostic tool. However, the sensitivity of PCR is <100%, and combining PCR with serologic testing at the first visit appears to be the best strategy for early diagnosis of acute anaplasmosis. In cases of high suspicion for HGA in patients without any diagnosis at the first visit, a second serologic test more than four weeks later can be helpful. A multiplex approach could also be used in such cases to look for differential diagnoses. The study was published in the May 2019 issue of the journal Emerging Infectious Diseases.

Related Links:
University of Strasbourg


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Thyroid Test
Anti-Thyroid EIA Test
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.